| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| Vivus Inc. v. Actavis Labs. FL Inc., 14-3786 (D.N.J.) | Qsymia® (phentermine / topiramate) | 7,056,890
7,553,818 7,659,256 7,674,776 8,580,298 8,580,299 |
Actavis to start selling its generic product on Dec. 1, 2024, or earlier “under certain circumstances.” Should Actavis begin selling a generic before its 2024 deadline, Vivus will collect royalties. |
| Eli Lilly and Co. v. Actavis Labs. UT Inc., 16-1119 (E.D. Va.) | Cialis® (tadalafil tablets) | 6,943,166 | Eli Lilly retains exclusivity over Cialis market until at least Sept. 27, 2018. Eli Lilly and generic defendants entered into a royalty-bearing license agreement. |
| Purdue Pharma L.P. v. Mylan Pharms. Inc., 15-1155 (D. Del.) | OxyContin® (oxycodone HCl extended-release tablets) | 9,073,933 | N/A |
| Amgen v. Apotex Inc., 16-0926 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| Amgen Inc. v. Micro Labs Ltd., 16-0854 (D. Del.) | Sensipar® (cinacalcet tablets) | 9,375,405 | N/A |
| AstraZeneca Pharms. LP v. Amneal Pharms. LLC, 15-1139 (D. Del.) | Byetta® (exenatide for injection) | 6,872,700 6,902,744 |
N/A |
| AstraZeneca AB v. Torrent Pharma Inc., 15-3375 (D.N.J.) | Daliresp® (roflumilast tablets) | 5,712,298 8,536,206 8,604,064 8,618,142 |
N/A |
